Category Archives: Top News
Penny Stock Pick Feature BPAX Biosante Pharmaceuticals, Inc.
We have added Biosante Pharmaceuticals, Inc. (BPAX): Nasdaq to our featured and our watch list today. As our subscribers know we just love the pharma tech plays specially the smaller ones as they could have potential for big moves. Biosante Pharmaceuticals, Inc. (BPAX): Nasdaq focuses on products for female sexual health, menopause, contraception, and male [...]
Myrexis Reports Anti-Tumor Activity in a Subset of Patients From Ongoing Phase 2 Azixa
Myrexis. (Nasdaq: MYRX) a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced a poster presentation of its lead product candidate Azixa(TM) (verubulin, MPC-6827) at the 2010 Society for Neuro-Oncology Scientific Meeting and Education Day in Montreal, Canada. Dr. Sean Grimm of the Northwestern University Brain Tumor Institute was the [...]
Alexza: FDA declines treatment for agitation
Alexza Pharmaceuticals, Inc. (Nasdaq:ALXA – News) Alexza Pharmaceuticals Inc., the Mountain View, Calif., drug developer, said on Monday that the U.S. Food and Drug Administration declined to clear for marketing AZ-004, a potential rapid treatment for agitation in patients with schizophrenia or bipolar disorder. The drug, generically loxapine, is taken by inhalation. In a complete [...]
IDIX Conference call today at 8:30 am ET
Conference call today at 8:30 am ET
Inhibitex Successfully Completes Phase 1a Trial of INX-189
Inhibitex, Inc. (Nasdaq:INHX – News)announced today that it has successfully completed a Phase1a, first-in-man, single ascending dose trial of INX-189, its nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. In this trial, 42 healthy volunteers received either a single oral dose of INX-189, ranging from 3 mg to 100 [...]
Alexza’s Staccato® Nicotine Licensed to Cypress Bioscience
Alexza Pharmaceuticals, Inc. (Nasdaq:ALXA – News) announced today that it has licensed its Staccato nicotine technology to Cypress Bioscience, Inc. (Nasdaq:CYPB – News). The Staccato nicotine technology is a novel electronic multidose delivery system designed to help people stop smoking. The Staccato nicotine technology is intended to improve on a well-validated smoking cessation approach by [...]
FDA panel rejects Jazz drug
Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) U.S. advisory panel on Friday rejected a Jazz Pharmaceuticals Inc (JAZZ.O) Nasdaqmedicine to treat the pain disorder fibromyalgia amid concerns the product could be misused as a “date-rape” drug. A Food and Drug Administration advisory committee voted 20-2 against recommending approval of sodium oxybate or JZP-6. The medicine contains a [...]
RPRX has received positive written feedback from the FDA
Repros Therapeutics Inc. (NasdaqCM:RPRX) today announced that the Company has received positive written feedback from the FDA (the “Agency”) regarding the Company’s drug candidate Androxal®. The Agency concurred with Repros’ indication statement for the use of Androxal in the treatment of secondary hypogonadism in men wishing to preserve fertility. In the written advice letter the [...]
Penny Stock Pick Feature ALXA Alexza Pharmaceuticals, Inc.
We have added Alexza Pharmaceuticals, Inc. (ALXA): Nasdaq to our featured and our watch list today with the upcoming FDA meeting in October for AZ-004 Staccato loxapine, we ask you to do some research on this company. We just love the pharma tech plays specially the smaller ones as they could have potential for big [...]
FDA Reject VVUS new drug Qnexa
Vivus Inc’s VVUS :NASDAQ food and Drug Administration panel has voted 10-6 against Vivus Inc.’s Qnexa citing the experimental obesity treatment’s negative side effects. Federal health advisers say the negative effects on concentration and memory outweigh its ability to help patients lose weight. The vote deals a major setback to the Mountainview, Calif., drugmaker which [...]